Pharmaniaga Berhad Past Earnings Performance
Past criteria checks 3/6
Pharmaniaga Berhad's earnings have been declining at an average annual rate of -22.1%, while the Healthcare industry saw earnings growing at 21.8% annually. Revenues have been growing at an average rate of 4.8% per year.
Key information
-22.1%
Earnings growth rate
-22.0%
EPS growth rate
| Healthcare Industry Growth | 31.5% |
| Revenue growth rate | 4.8% |
| Return on equity | n/a |
| Net Margin | 2.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry
Jul 18
Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S
May 09Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate
Apr 19Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price
Oct 03Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?
Jul 19Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?
Feb 18Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital
Dec 10Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts
Nov 24We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings
Aug 27Revenue & Expenses Breakdown
How Pharmaniaga Berhad makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,623 | 94 | 206 | 0 |
| 30 Jun 24 | 3,479 | -56 | 285 | 0 |
| 31 Mar 24 | 3,489 | -57 | 297 | 0 |
| 31 Dec 23 | 3,404 | -80 | 302 | 0 |
| 30 Sep 23 | 3,477 | -689 | 377 | 0 |
| 30 Jun 23 | 3,487 | -654 | 300 | 0 |
| 31 Mar 23 | 3,399 | -655 | 295 | 0 |
| 31 Dec 22 | 3,481 | -630 | 293 | 0 |
| 30 Sep 22 | 3,330 | 100 | 224 | 0 |
| 30 Jun 22 | 4,568 | 164 | 326 | 0 |
| 31 Mar 22 | 4,984 | 177 | 322 | 0 |
| 31 Dec 21 | 4,815 | 172 | 306 | 0 |
| 30 Sep 21 | 4,738 | 80 | 341 | 0 |
| 30 Jun 21 | 3,230 | 32 | 219 | 0 |
| 31 Mar 21 | 2,699 | 28 | 205 | 0 |
| 31 Dec 20 | 2,725 | 27 | 209 | 0 |
| 30 Sep 20 | 2,806 | -145 | 223 | 0 |
| 30 Jun 20 | 2,898 | -146 | 231 | 0 |
| 31 Mar 20 | 2,854 | -146 | 229 | 0 |
| 31 Dec 19 | 2,821 | -149 | 230 | 0 |
| 30 Sep 19 | 2,701 | 34 | 211 | 0 |
| 30 Jun 19 | 2,572 | 48 | 197 | 0 |
| 31 Mar 19 | 2,553 | 44 | 208 | 0 |
| 31 Dec 18 | 2,385 | 42 | 205 | 0 |
| 30 Sep 18 | 2,402 | 60 | 218 | 0 |
| 30 Jun 18 | 2,388 | 48 | 233 | 0 |
| 31 Mar 18 | 2,324 | 52 | 222 | 0 |
| 31 Dec 17 | 2,324 | 54 | 227 | 0 |
| 30 Sep 17 | 2,294 | 31 | 228 | 0 |
| 30 Jun 17 | 2,234 | 41 | 231 | 0 |
| 31 Mar 17 | 2,248 | 46 | 235 | 0 |
| 31 Dec 16 | 2,189 | 46 | 224 | 0 |
| 30 Sep 16 | 2,286 | 62 | 229 | 0 |
| 30 Jun 16 | 2,296 | 69 | 214 | 0 |
| 31 Mar 16 | 2,277 | 71 | 214 | 0 |
| 31 Dec 15 | 2,189 | 84 | 212 | 0 |
| 30 Sep 15 | 2,136 | 105 | 203 | 0 |
| 30 Jun 15 | 2,114 | 100 | 209 | 0 |
| 31 Mar 15 | 2,126 | 99 | 205 | 0 |
| 31 Dec 14 | 2,123 | 94 | 197 | 0 |
| 30 Sep 14 | 2,064 | 78 | 186 | 0 |
| 30 Jun 14 | 2,002 | 67 | 176 | 0 |
| 31 Mar 14 | 1,915 | 57 | 172 | 0 |
Quality Earnings: PHARMA has high quality earnings.
Growing Profit Margin: PHARMA became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHARMA has become profitable over the past 5 years, growing earnings by -22.1% per year.
Accelerating Growth: PHARMA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PHARMA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (3.9%).
Return on Equity
High ROE: PHARMA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 05:11 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharmaniaga Berhad is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hsien Jin Lam | CGS International |
| Yee Low | Hong Leong Investment Bank Berhad |
| Ping-Khoon Choo | Kenanga Research |